COVID-19 Vaccine Antibody Responses in Community-dwelling Adults to 48 weeks Post Primary Vaccine Series

Overview

Journal iScience

Publisher Cell Press

Date 2023 Apr 19

PMID 37073374

Authors

Sharon L Walmsley

Leah Szadkowski

Bradly Wouters

Rosemarie Clarke

Karen Colwill

Paula Rochon

Michael Brudno

Rizanni Ravindran

Janet Raboud

Allison McGeer

Amit Oza

Christopher Graham

Amanda Silva

Dorin Manase

Peter Maksymowsky

Laura Parente

Roaya Monica Dayam

Jacqueline Simpson

Adrian Pasculescu

Anne-Claude Gingras

Affiliations

Soon will be listed here.

Abstract

We report a decentralized prospective cohort study of self-reported adverse events and antibody responses to COVID vaccines derived from dried blood spots. Data are presented for 911 older (aged >70 years) and 375 younger (30-50 years) recruits to 48 weeks after the primary vaccine series. After a single vaccine, 83% younger and 45% older participants had overall seropositivity (p < 0.0001) increasing to 100/98% with the second dose, respectively (p = 0.084). A cancer diagnosis (p = 0.009), no mRNA-1273 vaccine doses (p <0 .0001), and older age (p <0 .0001) predicted lower responses. Antibody levels declined in both cohorts at 12 and 24 weeks increasing with booster doses. At 48 weeks, for participants with 3 vaccine doses, the median antibody levels were higher in the older cohort (p = 0.04) with any dose of mRNA-1273 (p <0 .0001) and with COVID infection (p <0 .001). The vaccines were well tolerated. Breakthrough COVID infections were uncommon (16% older cohort, 29% younger cohort; p < 0.0001) and mild

Citing Articles

Quantitating SARS-CoV-2 neutralizing antibodies from human dried blood spots.

Berman K, Van Slyke G, Novak H, Rock J, Bievenue R, Damjanovic A Microbiol Spectr. 2024; :e0084624.

PMID: 39470282 PMC: 11619372. DOI: 10.1128/spectrum.00846-24.

Declining Levels of Neutralizing Antibodies to SARS-CoV-2 Omicron Variants Are Enhanced by Hybrid Immunity and Original/Omicron Bivalent Vaccination.

Walmsley S, Nabipoor M, Qi F, Lovblom L, Ravindran R, Colwill K Vaccines (Basel). 2024; 12(6).

PMID: 38932293 PMC: 11209254. DOI: 10.3390/vaccines12060564.

Quantitating SARS-CoV-2 Neutralizing Antibodies from Human Dried Blood Spots.

Berman K, Van Slyke G, Novak H, Rock J, Bievenue R, Damjanovic A bioRxiv. 2024; .

PMID: 38562708 PMC: 10983952. DOI: 10.1101/2024.03.18.585599.

Effect of the number of coronavirus disease 2019 (COVID-19) vaccination shots on the occurrence of pneumonia, severe pneumonia, and death in SARS-CoV-2-infected patients.

Xin S, Chen W, Yu Q, Gao L, Lu G Front Public Health. 2024; 11:1330106.

PMID: 38259762 PMC: 10800481. DOI: 10.3389/fpubh.2023.1330106.

Predictors of Breakthrough SARS-CoV-2 Infection after Vaccination.

Walmsley S, Nabipoor M, Lovblom L, Ravindran R, Colwill K, Mcgeer A Vaccines (Basel). 2024; 12(1).

PMID: 38250849 PMC: 10820583. DOI: 10.3390/vaccines12010036.

References

Klein N, Lewis N, Goddard K, Fireman B, Zerbo O, Hanson K . Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA. 2021; 326(14):1390-1399. PMC: 8511971. DOI: 10.1001/jama.2021.15072. View

Accorsi E, Britton A, Fleming-Dutra K, Smith Z, Shang N, Derado G . Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. JAMA. 2022; 327(7):639-651. PMC: 8848203. DOI: 10.1001/jama.2022.0470. View

Morley G, Taylor S, Jossi S, Perez-Toledo M, Faustini S, Marcial-Juarez E . Sensitive Detection of SARS-CoV-2-Specific Antibodies in Dried Blood Spot Samples. Emerg Infect Dis. 2020; 26(12):2970-2973. PMC: 7706975. DOI: 10.3201/eid2612.203309. View

Muller L, Andree M, Moskorz W, Drexler I, Walotka L, Grothmann R . Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination. Clin Infect Dis. 2021; 73(11):2065-2072. PMC: 8135422. DOI: 10.1093/cid/ciab381. View

Steensels D, Pierlet N, Penders J, Mesotten D, Heylen L . Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273. JAMA. 2021; 326(15):1533-1535. PMC: 8406205. DOI: 10.1001/jama.2021.15125. View

Skowronski D, Kaweski S, Irvine M, Kim S, Chuang E, Sabaiduc S . Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada. CMAJ. 2022; 194(47):E1599-E1609. PMC: 9828974. DOI: 10.1503/cmaj.221335. View

Baden L, El Sahly H, Essink B, Kotloff K, Frey S, Novak R . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020; 384(5):403-416. PMC: 7787219. DOI: 10.1056/NEJMoa2035389. View

Holm Hansen C, Michlmayr D, Gubbels S, Molbak K, Ethelberg S . Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. Lancet. 2021; 397(10280):1204-1212. PMC: 7969130. DOI: 10.1016/S0140-6736(21)00575-4. View

Baric R . Emergence of a Highly Fit SARS-CoV-2 Variant. N Engl J Med. 2020; 383(27):2684-2686. DOI: 10.1056/NEJMcibr2032888. View

10.

Cromer D, Steain M, Reynaldi A, Schlub T, Wheatley A, Juno J . Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe. 2021; 3(1):e52-e61. PMC: 8592563. DOI: 10.1016/S2666-5247(21)00267-6. View

11.

Erice A, Varillas-Delgado D, Caballero C . Decline of antibody titres 3 months after two doses of BNT162b2 in non-immunocompromised adults. Clin Microbiol Infect. 2021; 28(1):139.e1-139.e4. PMC: 8426320. DOI: 10.1016/j.cmi.2021.08.023. View

12.

Falsey A, Frenck Jr R, Walsh E, Kitchin N, Absalon J, Gurtman A . SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. N Engl J Med. 2021; 385(17):1627-1629. PMC: 8461567. DOI: 10.1056/NEJMc2113468. View

13.

DiazGranados C, Dunning A, Kimmel M, Kirby D, Treanor J, Collins A . Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014; 371(7):635-45. DOI: 10.1056/NEJMoa1315727. View

14.

Lin D, Gu Y, Xu Y, Wheeler B, Young H, Sunny S . Association of Primary and Booster Vaccination and Prior Infection With SARS-CoV-2 Infection and Severe COVID-19 Outcomes. JAMA. 2022; 328(14):1415-1426. PMC: 9513711. DOI: 10.1001/jama.2022.17876. View

15.

McDade T, McNally E, Zelikovich A, DAquila R, Mustanski B, Miller A . High seroprevalence for SARS-CoV-2 among household members of essential workers detected using a dried blood spot assay. PLoS One. 2020; 15(8):e0237833. PMC: 7428174. DOI: 10.1371/journal.pone.0237833. View

16.

Collier D, Ferreira I, Kotagiri P, Datir R, Lim E, Touizer E . Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature. 2021; 596(7872):417-422. PMC: 8373615. DOI: 10.1038/s41586-021-03739-1. View

17.

Meyers E, Heytens S, Formukong A, Vercruysse H, De Sutter A, Geens T . Comparison of Dried Blood Spots and Venous Blood for the Detection of SARS-CoV-2 Antibodies in a Population of Nursing Home Residents. Microbiol Spectr. 2021; 9(2):e0017821. PMC: 8557917. DOI: 10.1128/Spectrum.00178-21. View

18.

Mwimanzi F, Lapointe H, Cheung P, Sang Y, Yaseen F, Umviligihozo G . Older Adults Mount Less Durable Humoral Responses to Two Doses of COVID-19 mRNA Vaccine but Strong Initial Responses to a Third Dose. J Infect Dis. 2022; 226(6):983-994. PMC: 9129202. DOI: 10.1093/infdis/jiac199. View

19.

Wall E, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C . Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet. 2021; 397(10292):2331-2333. PMC: 8175044. DOI: 10.1016/S0140-6736(21)01290-3. View

20.

Colwill K, Galipeau Y, Stuible M, Gervais C, Arnold C, Rathod B . A scalable serology solution for profiling humoral immune responses to SARS-CoV-2 infection and vaccination. Clin Transl Immunology. 2022; 11(3):e1380. PMC: 8942165. DOI: 10.1002/cti2.1380. View